[go: up one dir, main page]

CU20120148A7 - METHODS AND COMPOSITIONS FOR INTRANASAL SUPPLY - Google Patents

METHODS AND COMPOSITIONS FOR INTRANASAL SUPPLY

Info

Publication number
CU20120148A7
CU20120148A7 CU2012000148A CU20120148A CU20120148A7 CU 20120148 A7 CU20120148 A7 CU 20120148A7 CU 2012000148 A CU2012000148 A CU 2012000148A CU 20120148 A CU20120148 A CU 20120148A CU 20120148 A7 CU20120148 A7 CU 20120148A7
Authority
CU
Cuba
Prior art keywords
methods
compositions
intranasal
supply
powder formulations
Prior art date
Application number
CU2012000148A
Other languages
Spanish (es)
Inventor
Ryoichi Nagata
Shunji Haruta
Original Assignee
Shin Nippon Biomedical Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Nippon Biomedical Lab filed Critical Shin Nippon Biomedical Lab
Publication of CU20120148A7 publication Critical patent/CU20120148A7/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M3/00—Automatic or semi-automatic exchanges
    • H04M3/42—Systems providing special services or facilities to subscribers
    • H04M3/50—Centralised arrangements for answering calls; Centralised arrangements for recording messages for absent or busy subscribers ; Centralised arrangements for recording messages
    • H04M3/51—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing
    • H04M3/5116—Centralised call answering arrangements requiring operator intervention, e.g. call or contact centers for telemarketing for emergency applications
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/90—Services for handling of emergency or hazardous situations, e.g. earthquake and tsunami warning systems [ETWS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/50—Connection management for emergency connections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W76/00—Connection management
    • H04W76/10—Connection setup
    • H04W76/15—Setup of multiple wireless link connections
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W8/00—Network data management
    • H04W8/18—Processing of user or subscriber data, e.g. subscribed services, user preferences or user profiles; Transfer of user or subscriber data
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Signal Processing (AREA)
  • Business, Economics & Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Management (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Environmental & Geological Engineering (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marketing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proveen en la presente métodos para la generación de formulaciones en polvo de vacuna seca.Las formulaciones en polvo de vacuna seca pueden ser usadas para administración intranasal. También se proveen métodos para estimular inmunidad mucosal local e inmunidad sistémica mediante administración de vacuna intranasal.Methods for generating dry vaccine powder formulations are provided herein. Dry vaccine powder formulations may be used for intranasal administration. Methods to stimulate local mucosal immunity and systemic immunity by intranasal vaccine administration are also provided.

CU2012000148A 2010-04-15 2012-10-12 METHODS AND COMPOSITIONS FOR INTRANASAL SUPPLY CU20120148A7 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32454210P 2010-04-15 2010-04-15
PCT/JP2011/002225 WO2011129120A1 (en) 2010-04-15 2011-04-15 Methods and compositions for intranasal delivery

Publications (1)

Publication Number Publication Date
CU20120148A7 true CU20120148A7 (en) 2013-01-30

Family

ID=44798502

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000148A CU20120148A7 (en) 2010-04-15 2012-10-12 METHODS AND COMPOSITIONS FOR INTRANASAL SUPPLY

Country Status (12)

Country Link
US (2) US9687536B2 (en)
EP (2) EP2689785B1 (en)
JP (5) JP5771626B2 (en)
KR (3) KR101960102B1 (en)
CN (3) CN107260689A (en)
BR (1) BR112012026116A2 (en)
CA (2) CA2993242C (en)
CU (1) CU20120148A7 (en)
ES (1) ES2874817T3 (en)
RU (1) RU2012144612A (en)
SG (1) SG184304A1 (en)
WO (1) WO2011129120A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101960102B1 (en) * 2010-04-15 2019-03-19 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. Methods and compositions for intranasal delivery
CA2858997C (en) 2011-12-16 2020-03-31 Indosys Limited Medicament unit dose cartridge and delivery device
TWI690322B (en) * 2012-10-02 2020-04-11 法商傳斯堅公司 Virus-containing formulations and their use
WO2014186754A2 (en) * 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN104208029B (en) * 2013-05-30 2017-06-06 上海医药工业研究院 A kind of nose vaccine combination powder preparation and preparation method thereof
EP3041504B1 (en) 2013-09-03 2021-08-25 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
EP4008307A1 (en) * 2013-09-24 2022-06-08 Satsuma Pharmaceuticals, Inc. Intranasal dhe formulation for the treatment of headache
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial vaccine formulations
EP3127550A1 (en) * 2015-08-07 2017-02-08 HSC Development GmbH Stabilizing composition for dry formulation of virus
US11311615B2 (en) * 2015-09-16 2022-04-26 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
GB201610628D0 (en) * 2016-06-17 2016-08-03 Mihranyan Albert New compositions
AU2017327009A1 (en) * 2016-09-19 2019-04-04 Vaxess Technologies, Inc. Vaccine formulations with increased stability
US11022115B2 (en) 2017-06-02 2021-06-01 Purdue Research Foundation Controlled variable delivery external gear machine
JPWO2019021957A1 (en) * 2017-07-25 2020-07-09 第一三共株式会社 Nasal dry powder pharmaceutical composition
GB201713899D0 (en) 2017-08-30 2017-10-11 Indosys Ltd Multi-dose medicament delivery device
CA3083953A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
AU2019336940B2 (en) * 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
EP3893877A4 (en) 2018-12-11 2022-09-14 Satsuma Pharmaceuticals, Inc. COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OR PREVENTION OF HEADACHES
MX2021009837A (en) * 2019-02-15 2021-09-10 Serum Inst Of India Pvt Ltd Live attenuated influenza vaccine composition and process for preparation thereof.
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination
US11621604B2 (en) 2020-02-16 2023-04-04 Purdue Research Foundation Integrated electro-hydraulic machine
MX2022011539A (en) * 2020-03-24 2022-10-13 Byung Chul Ahn Method for producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof.
CN113583970B (en) * 2021-07-29 2023-05-12 吉林大学 A medicine for preventing or resisting coronavirus transmission and pathopoiesia, and its preparation method
WO2024047351A1 (en) 2022-09-01 2024-03-07 Therakind Limited Dry powder medicament delivery device
AU2023388890A1 (en) * 2022-12-07 2025-06-26 Daocheng Zhu Formulation and use of a fusion protein
WO2024228212A1 (en) * 2023-05-01 2024-11-07 Biovet Private Limited Bio-lumpivaxin formulations and method of preparation thereof
WO2024246607A1 (en) * 2023-05-31 2024-12-05 Shin Nippon Biomedical Laboratories, Ltd. Compositions for enhanced mucosal penetration
GB202403611D0 (en) 2024-03-13 2024-04-24 Therakind Ltd Improved multi-dose medicament delivery device
CN118924744A (en) * 2024-07-29 2024-11-12 复旦大学 Application of small molecule inhibitor HA15 in resisting hepatitis B virus

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009819A1 (en) * 1992-11-03 1994-05-11 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
CN1193745C (en) * 2001-02-27 2005-03-23 国家医药管理局上海医药工业研究院 Salmon calcitonin snuff and its prepn
MXPA04004726A (en) 2001-11-19 2004-07-30 Becton Dickinson Co Pharmaceutical compositions in particulate form.
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
DK1701738T3 (en) * 2003-12-17 2015-03-30 Wyeth Llc Process for preparing storage-stable RSV compositions
US20060292173A1 (en) * 2004-12-13 2006-12-28 Macadam Donald H Multibacterial vaccines and uses thereof
PT1954308E (en) 2005-09-16 2011-11-03 Merial Ltd Stabilizers for freeze-dried vaccines
RU2008117396A (en) 2005-10-04 2009-11-10 Альк-Абелло А/С (Dk) SOLID VACCINE COMPOSITION
CN101296705A (en) * 2005-10-04 2008-10-29 阿尔克-阿贝洛有限公司 Solid vaccine formulation
AU2007215080A1 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
JP2009534303A (en) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー Preserving influenza vaccines that are not refrigerated
ITMI20061117A1 (en) * 2006-06-09 2007-12-10 Michele Bonanomi A PHARMACEUTICAL COMPOSITION FOR THE SUBLINGUAL ADMINISTRATION OF VACCINI METHOD FOR ITS PREPARATION AND USES
JP2010502747A (en) 2006-09-08 2010-01-28 ベクトン・ディキンソン・アンド・カンパニー A stable powder formulation of alum-adsorbed vaccine
SG10202012986SA (en) * 2006-09-29 2021-01-28 Ligocyte Pharmaceuticals Inc Norovirus vaccine formulations
EP2116264B1 (en) 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
DK2829282T3 (en) * 2007-03-22 2018-01-02 Univ Colorado Regents Process for preparing an immunologically active adjuvant-linked dried vaccine composition
WO2009006299A2 (en) 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
JP5689687B2 (en) * 2008-03-05 2015-03-25 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ Method for stabilizing an adjuvant-containing vaccine composition
CN101601860A (en) * 2008-06-13 2009-12-16 中国科学院过程工程研究所 Vaccine
KR101707569B1 (en) 2008-08-01 2017-02-16 감마 백신즈 피티와이 리미티드 Influenza vaccines
JP2012526726A (en) * 2009-05-15 2012-11-01 株式会社新日本科学 Intranasal pharmaceutical composition with improved pharmacokinetics
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
JP5491119B2 (en) 2009-10-02 2014-05-14 日東電工株式会社 Pharmaceutical composition containing drug-containing microparticles and method for producing the same
KR101960102B1 (en) 2010-04-15 2019-03-19 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. Methods and compositions for intranasal delivery
AU2012244077B2 (en) 2010-04-15 2015-06-18 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery

Also Published As

Publication number Publication date
EP2558120A4 (en) 2013-08-28
CN103126996A (en) 2013-06-05
CN107260689A (en) 2017-10-20
JP2016006119A (en) 2016-01-14
JP2019104751A (en) 2019-06-27
CA2993242C (en) 2020-12-15
US10463723B2 (en) 2019-11-05
US20130129781A1 (en) 2013-05-23
JP2017186377A (en) 2017-10-12
KR20190028555A (en) 2019-03-18
RU2012144612A (en) 2014-05-20
CN102933230B (en) 2016-03-02
CA2796593A1 (en) 2011-10-20
WO2011129120A1 (en) 2011-10-20
EP2689785B1 (en) 2021-05-19
JP6827488B2 (en) 2021-02-10
KR20130083376A (en) 2013-07-22
KR101960102B1 (en) 2019-03-19
KR20130064741A (en) 2013-06-18
ES2874817T3 (en) 2021-11-05
US20130273120A1 (en) 2013-10-17
BR112012026116A2 (en) 2016-06-28
CA2796593C (en) 2020-12-15
JP5771626B2 (en) 2015-09-02
SG184304A1 (en) 2012-11-29
EP2689785A1 (en) 2014-01-29
JP2013126989A (en) 2013-06-27
CN102933230A (en) 2013-02-13
EP2558120A1 (en) 2013-02-20
JP2013523602A (en) 2013-06-17
KR102136036B1 (en) 2020-07-20
CA2993242A1 (en) 2011-10-20
US9687536B2 (en) 2017-06-27

Similar Documents

Publication Publication Date Title
CU20120148A7 (en) METHODS AND COMPOSITIONS FOR INTRANASAL SUPPLY
CY1120790T1 (en) MRNA TOY CFTR COMPOSITIONS AND RELATED METHODS AND USES
PT3061454T (en) VETERINARY ORAL PARASITICID COMPOSITIONS INCLUDING ACTIVE AGENTS OF SYSTEMIC ACTION, METHODS AND THEIR USES
CO6771417A2 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
UY34333A (en) ? METHODS AND COMPOSITIONS FOR WEED CONTROL, AND METHODS TO REDUCE THE EXPRESSION OF ENZYME DHPS?
EA201490381A1 (en) SYNTHETIC NANOSEAGES WHICH STIMULATE THE FORMATION OF HUMORAL IMMUNE RESPONSE AND IMMUNE RESPONSE MEDIATED BY CYTOTOXIC T-LYMPHOCYTES (CTL)
DOP2016000287A (en) COMPOSITIONS AND METHODS TO MODULATE THE EXPRESSION OF TTR AND VH
CO6801729A2 (en) Compositions and methods to modulate the fxr
PE20150627A1 (en) C17-ALCANDIILO AND ALKENDIYL DERIVATIVES OF OLEANOLIC ACID AND THEIR METHODS OF USE
CO7240373A2 (en) Proliposomal testosterone formulations
ECSP18010481A (en) PLINABULIN COMPOSITIONS
MX352324B (en) Multivalent synthetic nanocarrier vaccines.
UY34406A (en) COMPOUNDS AND METHODS TO IMPROVE THE INMUNE IMMUNE RESPONSE
CO7350620A2 (en) New pyridine derivatives
CY1117209T1 (en) COMPOSITIONS INCLUDING 15-DAYS AND METHODS OF USING OWNERS
CR20130521S (en) APPARATUS TO HAIR HAIR
PH12017500836A1 (en) Transdermal formulations
UA115357C2 (en) Pyridin-4-yl derivatives
WO2013177444A3 (en) Influenza vaccine constructs
EA201170294A1 (en) METHODS OF TREATMENT OF REPERFUSION DAMAGE
CY1116004T1 (en) OXAZOLYL-Methyl-ethyl derivative as ALX receptor agonists
CR20150282A (en) METHOD FOR SYNCHRONIZATION OF INSEMINATION TIME IN YOUNG PIGS
UY33812A (en) Synchronous Wind Generator
UY34223A (en) FORMULATIONS OF (NEW TRIMETOXIFENILAMINO) PYRIMIDINYL
UY33975A (en) Otamixaban formulations with improved stability